Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of MLN8237 in Combination With Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma

Trial Profile

A Phase I Study of MLN8237 in Combination With Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alisertib (Primary) ; Bortezomib (Primary) ; Rituximab
  • Indications B-cell lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions

Most Recent Events

  • 21 Mar 2025 Planned End Date changed from 5 Mar 2025 to 19 Mar 2026.
  • 04 Dec 2018 Results assessing safety and efficacy of Alisertib in combination with bortezomib and rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
  • 16 Feb 2018 Planned primary completion date changed from 30 Dec 2017 to 31 Mar 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top